WHO panel recommends Emergency Use Listing status for Covaxin – ET TravelWorld

0 0
Read Time:1 Minute, 45 Second

WHO panel recommends Emergency Use Listing status for CovaxinThe Technical Advisory Group (TAG), an independent advisory committee of the World Health Organisation (WHO), has recommended Emergency Use Listing (EUL) status for the Bharat Biotech Covid-19 vaccine – Covaxin, sources in the know of the development said.

The WHO is in the process of evaluating Covaxin’s clinical trial data for use of EUL. The TAG on October 26 had sought “additional clarifications” from the company for Covaxin to conduct a final “risk-benefit assessment” for Emergency Use Listing of the vaccine.

The World Health Organisation’s technical advisory group met on Tuesday to review data on Covaxin for the Emergency Use Listing of India’s indigenously-made vaccine.

“The Technical Advisory Group of WHO has recommended Emergency Use Listing status for Covaxin,” a source said. The TAG-EUL is an independent advisory group that provides recommendations to WHO on whether a Covid-19 vaccine can be listed for emergency use under the EUL procedure.”WHO Technical Advisory Group for Emergency Use Listing (EUL) is an independent advisory group that provides recommendations to WHO on whether a #COVID19 vaccine can be listed for emergency use under the EUL procedure,” the WHO had tweeted earlier.

The World Health Organisation’s technical advisory group is scheduled to meet on November 3 for a final risk-benefit assessment for the Emergency Use Listing of the Bharat Biotech vaccine.

The global health body had also tweeted a video of WHO Health Emergencies Programme Executive Director Dr Mike Ryan, who said the World Health Organisation “is very clear that we want all countries to recognise EUL vaccines that have been given an Emergency Use Listing (EUL) by the WHO advisory process. But it’s also very important that WHO, when it makes a recommendation like that, is making that globally.”

Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic Covid-19 and 65.2 per cent protection against the new Delta variant. In June, the company said it concluded the final analysis of Covaxin efficacy from Phase 3 trials.

Bharat Biotech’s Covaxin and AstraZeneca and Oxford University’s Covishield are the two widely used vaccines in India.



Source link

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post USA is the best country to visit in Autumn, according to Instagram
Next post Glad to see Covaxin get the Emergency Use Listing approval: WHO chief – ET TravelWorld

Average Rating

5 Star
0%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Leave a Reply

Your email address will not be published. Required fields are marked *

Social profiles